VitaLonga

Human study · Aging · 16 Nov 2026

In 1,641 memory-clinic patients, two copies of APOE4 lined up with much higher odds of an amyloid scan

Source: Neurology

What the research found

An observational multicenter study was published online on 16 November 2026. It used Medicare beneficiaries with mild cognitive impairment or dementia from the IDEAS study who were also in the Amyloid Neuroimaging and Genetics Initiative. Of 1,641 people, 1,219 had mild cognitive impairment and 422 had dementia. They were aged 74.3 years on average (standard deviation 5.6). 43.6 percent were female. Amyloid status used a local visual read and a Centiloid cut point of 24.4. Against APOE3/3, the odds of a positive visual read were higher for APOE2/4 (odds ratio 3.10, 95 percent CI 1.58 to 6.47, p=0.002), APOE3/4 (4.52, 95 percent CI 3.50 to 5.86, p less than 0.001), and APOE4/4 (26.34, 95 percent CI 12.93 to 63.39, p less than 0.001). A Centiloid definition gave a similar pattern. Amyloid burden rose across genotypes (p less than 0.001, partial eta squared 0.20). Among positive scans, APOE4 showed a wider cortical signal and APOE2 a more focal one. An APOE3/4 interaction showed higher odds of a positive visual read among females. APOE4/4 also lined up with dementia and with amnestic mild cognitive impairment. The sample was limited to people who already had cognitive impairment, and the authors note limited racial and ethnic diversity. Clinic data, not a prevention trial. DOI 10.1212/WNL.0000000000218689. Not medical advice.

Evidence level: Human study. A study in people, but an association isn't proof of cause.

Read the original at Neurology

More aging news